{"nctId":"NCT03232073","briefTitle":"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis","startDateStruct":{"date":"2017-07-05","type":"ACTUAL"},"conditions":["Multiple Sclerosis"],"count":877,"armGroups":[{"label":"Ponesimod","type":"EXPERIMENTAL","interventionNames":["Drug: Ponesimod"]}],"interventions":[{"name":"Ponesimod","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed informed consent\n2. Subjects with MS having completed the double-blind treatment in the core study as scheduled\n3. Compliance with teriflunomide elimination procedure\n4. Women of childbearing potential (WOCBP) must have a negative pre-treatment urine pregnancy test, must agree to undertake 4-weekly urine pregnancy tests, and must have been using reliable methods of contraception. Fertile male subjects participating in the study must agree to use a condom.\n\nExclusion Criteria:\n\n1. Any of the following cardiovascular conditions on Day 1 pre-dose:\n\n   1. Resting heart rate (HR) \\< 50 bpm;\n   2. Presence of second degree atrioventricular (AV) block or third degree AV block or a QTcF interval \\> 470 ms (females), \\> 450 ms (males);\n2. Any of the following alerts from central laboratory at Visit 14 of the core study (EOT) which was confirmed as an alert at repeated testing or not repeated prior to FU1 of the core study:\n\n   1. Lymphocyte count: \\< 0.2 x 109/L;\n   2. Neutrophil count \\<1.0 × 109/L;\n   3. Platelet count \\< 50 × 109/L;\n   4. Creatinine clearance \\< 30 mL/min\n3. At Visit 14 of the core study (EOT) \\>30% decrease from core study baseline FEV1 and/or FVC;\n4. Clinically significant, persistent respiratory AEs (e.g., dyspnea) not resolved prior to first dosing in the extension study.\n5. Macular edema at any time between Visit 1 (Screening) in the core study and Day 1 of the extension study.\n6. Presence of the following at core study Visit 14 (EOT, Week 108), FU1, or abbreviated visit FU2, or on Day 1 of the extension study pre-dose:\n\n   1. Suspected opportunistic infection of the CNS or any other infection which, in the opinion of the investigator, contraindicates re-start of the study drug;\n   2. Stevens-Johnson syndrome or toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms.\n7. Need for and intention to administer forbidden study treatment-concomitant therapy\n8. Women who are pregnant or lactating.\n9. Male subjects wishing to parent a child;\n10. Treatment with any MS Disease Modifying Therapies;\n11. Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study;\n12. Subjects unlikely to comply with the extension study protocol based on investigator best judgment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Confirmed Relapse Rate (ARR)","description":"ARR: number of confirmed relapses per patient-year. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours, in the absence of fever or infection. A confirmed relapse is identified when a patient's symptoms worsen as indicated by an increase in their Expanded Disability Status Scale (EDSS) or Functional Systems (FS) scores, consistent with previous clinically stable assessments. Specific criteria for a confirmed relapse include: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0 (normal)-10 (death due to MS).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.143","spread":null},{"groupId":"OG001","value":"0.184","spread":null}]}]}]},{"type":"PRIMARY","title":"Time From Core Study Randomization to First Confirmed Relapse","description":"Time to first confirmed relapse: date of first confirmed relapse (in either core or extension study) minus date of randomization in core study+1 day. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse are: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"402.71","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to First 12-week Confirmed Disability Accumulation (CDA)","description":"Time to first 12-week CDA is defined as start date of the first 12-week CDA minus date of randomization in the core study + 1 day. A 12-week CDA is defined as a 12-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 12-weeks. CDA is defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \\>=5.5, confirmed after 12 weeks. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to First 24-week Confirmed Disability Accumulation (CDA)","description":"Time to first 24-week CDA was defined as start date of the first 24-week CDA minus date of randomization in the core study + 1 day. A 24-week CDA was defined as a 24-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 24-weeks. CDA was defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \\>=5.5, confirmed after 24 weeks. EDSS was an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Absence of Relapses","description":"Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"51.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Expanded Disability Status Scale (EDSS)","description":"EDSS is ordinal clinical rating scale based on standard neurological examination for assessing neurological disability and impairment in MS. Seven FS scores were rated on a scale ranged from 0 to 5 or 6 to assess visual, brain, stem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral functions while ambulation was scored on scale ranged from 0 to 12 to assess walking distance and assistance. Individual FS scores were then used in conjugation with ambulation score to obtain EDSS score which ranged from 0 (normal) to 10 (death due to MS) in 0.5 unit increments that represented higher levels of disability. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"1.008"},{"groupId":"OG001","value":"0.34","spread":"1.105"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study","description":"NEDA-3 up to extension EOS is defined by the absence of confirmed relapse, gadolinium-enhancing (Gd+ T1) lesions, new or enlarging T2 lesions, and 12-week CDA. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-3. Confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study","description":"NEDA-4 up to EOS is defined by the absence of confirmed relapse, Gd+ T1 lesions, new or enlarging T2 lesions, 12-week CDA until EOS, and absence of annual brain volume decrease \\>=0.4% from core baseline up to extension EOS. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-4. Confirmed relapse: when patient's symptoms worsen by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in core study for each outcome measure and each participant individually.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)","description":"Percent change from baseline in brain volume (PCBV) measured by MRI were reported. Normalized Brain Volume at core baseline was measured in cubic centimeter (cm\\^3). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":"2.179"},{"groupId":"OG001","value":"-2.72","spread":"2.024"}]}]}]},{"type":"PRIMARY","title":"Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI","description":"CUALs was calculated as sum of new T1 Gadolinium-enhanced (Gd+) lesions and new or enlarging T2 lesions (without double-counting of lesions) from baseline up to extension EOS based on the Magnetic resonance imaging (MRI). Average number of lesions per patient-year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.352","spread":null},{"groupId":"OG001","value":"1.954","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI","description":"Number of Gd+ T1 lesions measured by MRI were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. For this outcome measure, results presented here are for the Extension end-of-treatment visit.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.211","spread":null},{"groupId":"OG001","value":"0.395","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Number of New or Enlarging T2 Lesions Measured by MRI","description":"Cumulative number of new or enlarging T2 lesions measured by MRI were reported. Average number of lesions per year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.352","spread":null},{"groupId":"OG001","value":"1.951","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)","description":"Change from baseline in volume of MRI lesions (T2 lesions, T1 hypointense lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-435.7","spread":"2822.71"},{"groupId":"OG001","value":"91.5","spread":"3647.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165.6","spread":"1427.30"},{"groupId":"OG001","value":"309.4","spread":"1712.36"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)","description":"Number of participants with absence of MRI lesions (Gd+ T1 lesions, new or enlarging T2 lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)","description":"Percentage of Gd+ lesions at baseline evolving to PBHs were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"25.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"Number of participants with TEAEs were reported. An AE is any untoward medical event that occurs in a participants being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":null},{"groupId":"OG001","value":"410","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities","description":"Number of participants with treatment-emergent new morphological ECG abnormalities were reported. Treatment-emergent new morphological ECG abnormalities are defined as those ECG abnormalities occurring from start of treatment up to treatment end date + 15 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]}]},{"type":"PRIMARY","title":"Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate","description":"Actual values of 12-lead ECG measurements up to end of study treatment: heart rate were reported. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":"9.64"},{"groupId":"OG001","value":"67.6","spread":"9.33"}]}]}]},{"type":"PRIMARY","title":"Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcF","description":"Actual values of 12-lead ECG measurements up to end of study treatment: PR, QRS, QT, QTcB, QTcF were reported. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150.0","spread":"20.41"},{"groupId":"OG001","value":"153.3","spread":"20.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":"9.22"},{"groupId":"OG001","value":"93.3","spread":"10.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392.5","spread":"27.26"},{"groupId":"OG001","value":"391.0","spread":"25.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414.8","spread":"19.20"},{"groupId":"OG001","value":"413.8","spread":"19.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"406.9","spread":"17.78"},{"groupId":"OG001","value":"405.7","spread":"17.78"}]}]}]},{"type":"PRIMARY","title":"Change in Heart Rate (HR) From Baseline up to End of Study Treatment","description":"Change in heart rate (HR) from baseline up to end of study treatment were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"10.00"},{"groupId":"OG001","value":"-1.5","spread":"9.17"}]}]}]},{"type":"PRIMARY","title":"Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study Treatment","description":"Change in PR, QRS, QT, QTcB, QTcF from baseline up to end of study treatment were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"14.09"},{"groupId":"OG001","value":"2.0","spread":"14.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"6.79"},{"groupId":"OG001","value":"2.9","spread":"6.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"25.68"},{"groupId":"OG001","value":"8.9","spread":"21.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"16.75"},{"groupId":"OG001","value":"5.2","spread":"17.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"15.28"},{"groupId":"OG001","value":"6.5","spread":"14.18"}]}]}]},{"type":"PRIMARY","title":"Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) Values","description":"Absolute values in FEV1 and FVC values were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. Results are presented for extension end of treatment visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"0.768"},{"groupId":"OG001","value":"3.08","spread":"0.797"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.96","spread":"0.965"},{"groupId":"OG001","value":"4.04","spread":"1.031"}]}]}]},{"type":"PRIMARY","title":"Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)","description":"Percent change in FEV1 and FVC from baseline (%) were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. In this outcome measure, results were presented for extension end of treatment visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.96","spread":"13.356"},{"groupId":"OG001","value":"-6.75","spread":"12.323"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.09","spread":"11.793"},{"groupId":"OG001","value":"-3.93","spread":"12.141"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)","description":"Number of participants with treatment-emergent SAEs were reported. A SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. Treatment-emergent SAEs are defined as SAEs occurring from start of treatment up to treatment end date + 15 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)","description":"Number of participants with treatment-emergent AESIs were reported. AESIs included bradyarrhythmia occurred post-first dose, macular edema, bronchoconstriction, severe liver injury, serious opportunistic infections including progressive multifocal leukoencephalopathy (PML), skin cancer, non-skin malignancy, convulsions, unexpected neurological or psychiatric symptoms/signs (posterior reversible encephalopathy syndrome \\[PRES\\], acute disseminated encephalomyelitis \\[ADEM\\], and atypical MS relapses). Treatment-emergent AESIs are defined as AESIs occurring from start of treatment up to treatment end date + 15 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With AE Leading to Premature Discontinuation of Study Treatment","description":"Number of participants with AE leading to premature discontinuation of study treatment were reported. An AE is any untoward medical event that occurs in a participant being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVC","description":"Number of participants with treatment-emergent decrease from baseline \\>20% and \\>30% in FEV1 or FVC were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From Baseline","description":"Number of participants with treatment-emergent decrease of \\>20% points in percent predicted FEV1 and FVC from baseline were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOT","description":"Number of participants with a decrease of \\>=200 mL or \\>=12% in FEV1 or FVC from baseline to EOT were planned to be reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. This endpoint is not relevant as a substantial proportion of patients continued onto post-treatment disease-modifying therapy (DMT), hence it cannot provide an assessment of reversibility.","paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)","description":"Change in FEV1 and FVC (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.14","spread":"13.315"},{"groupId":"OG001","value":"-5.43","spread":"11.839"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.70","spread":"13.129"},{"groupId":"OG001","value":"-3.19","spread":"13.081"}]}]}]},{"type":"PRIMARY","title":"Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)","description":"Change in FEV1 and FVC (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.95","spread":"12.854"},{"groupId":"OG001","value":"-4.08","spread":"14.365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.48","spread":"13.727"},{"groupId":"OG001","value":"-1.98","spread":"15.747"}]}]}]},{"type":"PRIMARY","title":"Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline","description":"Absolute change in lung diffusion capacity as assessed by DL\\[CO\\] from baseline were reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"3.44"},{"groupId":"OG001","value":"0.1","spread":"4.17"}]}]}]},{"type":"PRIMARY","title":"Change in DL[CO] (% Predicted) From Baseline to EOT","description":"Change in DL\\[CO\\] (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"32.20"},{"groupId":"OG001","value":"-9.4","spread":"7.82"}]}]}]},{"type":"PRIMARY","title":"Change in DL[CO] (% Predicted) From Baseline to EOS","description":"Change in DL\\[CO\\] (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"39.38"},{"groupId":"OG001","value":"2.2","spread":"49.50"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: Heart Rate","description":"Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: heart rate were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":"8.73"},{"groupId":"OG001","value":"71.0","spread":"9.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.5","spread":"10.53"},{"groupId":"OG001","value":"69.0","spread":"10.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":"9.91"},{"groupId":"OG001","value":"65.1","spread":"8.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":"9.33"},{"groupId":"OG001","value":"67.8","spread":"10.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":"9.73"},{"groupId":"OG001","value":"67.6","spread":"10.01"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: PR, QRS, QT, QTcB, QTcF","description":"Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: PR, QRS, QT, QTcB, QTcF were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.8","spread":"17.66"},{"groupId":"OG001","value":"149.8","spread":"19.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150.5","spread":"17.25"},{"groupId":"OG001","value":"152.6","spread":"22.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150.1","spread":"16.60"},{"groupId":"OG001","value":"153.6","spread":"23.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152.3","spread":"17.73"},{"groupId":"OG001","value":"154.5","spread":"21.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150.7","spread":"17.82"},{"groupId":"OG001","value":"151.8","spread":"19.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":"11.06"},{"groupId":"OG001","value":"91.5","spread":"7.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":"11.42"},{"groupId":"OG001","value":"93.2","spread":"8.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":"11.71"},{"groupId":"OG001","value":"92.7","spread":"7.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":"11.60"},{"groupId":"OG001","value":"94.5","spread":"7.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":"10.48"},{"groupId":"OG001","value":"92.5","spread":"7.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391.5","spread":"24.80"},{"groupId":"OG001","value":"378.8","spread":"23.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396.7","spread":"28.76"},{"groupId":"OG001","value":"380.9","spread":"21.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"402.0","spread":"29.00"},{"groupId":"OG001","value":"386.0","spread":"19.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"400.2","spread":"27.78"},{"groupId":"OG001","value":"386.9","spread":"21.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"400.0","spread":"27.49"},{"groupId":"OG001","value":"383.9","spread":"23.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"416.2","spread":"19.05"},{"groupId":"OG001","value":"411.4","spread":"20.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"416.0","spread":"24.11"},{"groupId":"OG001","value":"407.6","spread":"22.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414.8","spread":"22.83"},{"groupId":"OG001","value":"401.7","spread":"20.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414.2","spread":"23.30"},{"groupId":"OG001","value":"410.1","spread":"22.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"418.0","spread":"20.30"},{"groupId":"OG001","value":"406.6","spread":"22.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"407.4","spread":"17.09"},{"groupId":"OG001","value":"400.0","spread":"18.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"409.2","spread":"20.58"},{"groupId":"OG001","value":"398.1","spread":"18.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"410.1","spread":"20.41"},{"groupId":"OG001","value":"396.2","spread":"16.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"409.0","spread":"20.97"},{"groupId":"OG001","value":"402.0","spread":"16.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"411.5","spread":"18.36"},{"groupId":"OG001","value":"398.5","spread":"18.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":439},"commonTop":["Covid-19","Alanine Aminotransferase Increased","Nasopharyngitis","Lymphopenia","Headache"]}}}